Hybio's Generic Weight-Loss Drug Prepares for FDA Review
📊 GOOGL — Piyasa Yorumu
■ neutral · 60%Since the news headline is not directly related to GOOGL, the market impact may be limited. Technical indicators point to a slight upward trend in the short term: RSI at 63 is in neutral territory, MACD is above the signal line, and the price is above both the 20-day and 50-day moving averages. However, after a 4.15% increase in the last 24 hours, some profit-taking or consolidation may occur. Therefore, as there is no clear directional signal, a neutral stance is maintained.
📊 LLY — Piyasa Yorumu
▼ down · 60%The news increases the competitive threat to LLY's dominance in the weight loss drug market. The price closed below the 20-day moving average, and the RSI is in neutral territory, indicating potential weakness in the short term. The MACD remains below the signal line, showing negative momentum. Despite a 6.5% rise in the last 24 hours, the uncertainty created by the news could trigger selling pressure. A bearish trend is expected in the short term.
📊 NVO — Piyasa Yorumu
▼ down · 60%Hybio's preparation for FDA review of its generic weight-loss drug could bring direct competition to Novo Nordisk's popular products such as Ozempic and Wegovy. This situation may pressure NVO's market share and revenue expectations. Technically, although the RSI is in neutral territory at 52.7, the MACD remains below the signal line and the stock is trading just under the SMA20. In the short term, the price is likely to show a downward trend due to the negative impact of this news.
📊 AMGN — Piyasa Yorumu
■ neutral · 60%Although the news concerns a generic drug that falls within AMGN's direct area of operation, it remains uncertain whether it poses a direct threat to the company's own weight-loss drug portfolio. Technical indicators do not provide a clear directional signal, with the RSI at 62 in neutral territory and the MACD hovering near its signal line. In the short term, the price staying above the 20-day moving average (359.38) is positive, but trading at a premium to the 50-day average (353.50) suggests that upside may be limited. Therefore, the impact of the news may be limited, and the market may await further catalysts.